Researchers are highlighting a major evidence gap around transgender cardiovascular health, including how hormone therapy, stress and wider healthcare access may affect risk. For trans and gender-diverse people, the message isn't to fear treatment, but to expect informed, individualised care and better research.

Essential Takeaways

  • The evidence is limited: Much existing research examines risk factors rather than overall cardiovascular outcomes.
  • Hormones aren't the whole story: Estrogen and testosterone may affect risks such as clotting or blood pressure, but findings remain mixed.
  • Stress matters: Discrimination, violence and chronic pressure can influence behaviours and conditions linked to heart disease.
  • Routine monitoring helps: Blood pressure, cholesterol, smoking, diabetes and family history all deserve attention.
  • Care should be personal: Decisions about hormone therapy belong with a qualified clinician who understands the patient's health history.

The research gap is impossible to ignore

Heart disease remains a leading cause of death in the United States, yet researchers say transgender and gender-diverse communities are still poorly represented in cardiovascular studies. A perspective published in the Journal of General Internal Medicine argues that this leaves clinicians working with an incomplete map, particularly when discussing gender-affirming hormone therapy.

The concern isn't that every trans person faces the same risk, or that hormone treatment should be treated as inherently dangerous. Rather, the available evidence often focuses on narrow measures, such as blood pressure or cholesterol, instead of tracking cardiovascular outcomes across diverse populations and over many years. The American Heart Association has similarly called for stronger, more inclusive cardiovascular research involving transgender and gender-diverse people.

That distinction matters. A snapshot of one risk factor can be useful, but it can't tell the whole story about someone's heart health.

Does hormone therapy raise cardiovascular risk?

The short answer is that it may influence some risks, but the picture is complicated. Guidance from the American College of Cardiology notes that estrogen therapy has been associated with concerns including blood clots, while testosterone treatment can affect blood pressure, cholesterol and red blood cell levels. The size and significance of those effects can vary with age, dose, route of administration and existing health conditions.

Some studies have reported higher rates of particular cardiovascular events among people receiving gender-affirming hormones, while other research has found different patterns. The American College of Cardiology says clinicians should consider the full clinical picture rather than treating hormone therapy as a single, uniform exposure.

That means the useful question isn't simply, "Are hormones safe?" It's, "What are the likely benefits and risks for this person, and how can treatment be monitored sensibly?"

Heart health extends beyond HRT

The researchers argue that an exclusive focus on hormones can obscure cardiovascular risk among trans people who don't use them. It can also overlook the social conditions that shape health long before someone arrives at a clinic.

Discrimination, harassment, violence and political hostility can create sustained psychological strain. The American Heart Association has linked chronic stress and social disadvantage with behaviours and conditions associated with cardiovascular disease, including smoking, substance use, high blood pressure and poorer access to preventive care.

This doesn't mean transphobia can be reduced to a simple medical cause-and-effect claim. The evidence is still developing. But it does suggest that cardiovascular research needs to examine housing, employment, healthcare access, mental health and safety alongside hormone use.

What should patients and clinicians monitor?

For anyone considering or receiving hormone therapy, regular health checks are a practical starting point. Blood pressure, cholesterol, diabetes risk, smoking status, weight, family history and previous clotting or cardiovascular problems can all help shape a safer care plan.

People taking testosterone may need monitoring of blood pressure and blood counts, while those taking estrogen may need a discussion about clotting risk and other personal factors. The American Heart Association advises that route of administration and individual medical history should be considered rather than relying on broad assumptions.

Patients shouldn't stop or change prescribed hormones without speaking to their clinician. A calm, evidence-based review is far safer than advice from an alarming social media post, even when that post sounds confident.

Better evidence would improve care for everyone

The authors' wider point is straightforward: transgender cardiovascular health needs dedicated, long-term research that includes people across the spectrum, whether or not they use gender-affirming hormones. That research should measure real cardiovascular outcomes, not just isolated laboratory changes.

Professional cardiology organisations are increasingly encouraging clinicians to build trans-inclusive care into ordinary practice. It shouldn't require a patient to become an expert in medical jargon just to ask whether their blood pressure, cholesterol or family history changes the conversation.

For now, the best approach is individualised care, honest discussion about uncertainty and routine prevention. Nobody should have to choose between gender-affirming treatment and being taken seriously about their heart.

It's a small but important shift: better questions can lead to safer, more respectful care.

Source Reference Map

Story idea inspired by: [1]

Sources by paragraph: